Publication: 3092

Publication: 3092

Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201)

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Clin Cancer Res vol 26 (4) 804-811

Year:: 2020
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:: 9

Parents:: 2301 3060
Children:: None

Program:: OGC
Primary Committee:: Experimental
Sec. Committees:

Pharmas:: Exelixis
Grants:: U10CA180821, U10CA180882, U10CA180836, U24CA196171, UG1CA189960, U10CA180863 (CCTG), W81XWH-17-1-0265; P30 CA014599; NIH/NIGMS T32GM007019,

Corr. Author:
Authors:: Jason J. Luke Daniel J. Olson Jacob B. Allred Carrie A. Strand Riyue Bao Yuanyuan Zha Timothy Carll Brian W. Labadie Bruno R. Bastos Marcus Butler Davide Hogg Pamela Munster Gary K. Schwartz

Networks:: 11030, CA824, COLUMBIA, LAPS-IL057, LAPS-MN026, LAPS-PA015, OH029

Study: Alliance-A091201
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords:: uveal melanoma, MET, cabozantinib, VEGFR